Search Results
You are looking at 1 - 5 of 5 items for
- Author: Ming Gao x
- Refine by access: Content accessible to me x
Search for other papers by Xiang Zhang in
Google Scholar
PubMed
Search for other papers by Ya Hu in
Google Scholar
PubMed
Search for other papers by Mengyi Wang in
Google Scholar
PubMed
Search for other papers by Ronghua Zhang in
Google Scholar
PubMed
Search for other papers by PeiPei Wang in
Google Scholar
PubMed
Search for other papers by Ming Cui in
Google Scholar
PubMed
Search for other papers by Zhe Su in
Google Scholar
PubMed
Search for other papers by Xiang Gao in
Google Scholar
PubMed
Search for other papers by Quan Liao in
Google Scholar
PubMed
Search for other papers by Yupei Zhao in
Google Scholar
PubMed
Parathyroid carcinoma (PCa) is a rare endocrine neoplasia that typically has unfavourable outcomes. The contribution of long non-coding RNAs (lncRNAs) to the development of malignant and benign parathyroid tumours remains largely unknown. In this study, we explored transcriptomic profiling of lncRNA and mRNA expression in 6 PCa, 6 parathyroid adenoma (PAd) and 4 normal parathyroid (PaN) tissues. In total, 2641 lncRNA transcripts and 2165 mRNA transcripts were differentially expressed between PCa and PAd. Enrichment analysis demonstrated that dysregulated transcripts were involved mainly in the extracellular matrix (ECM)–receptor interaction and energy metabolism pathways. Bioinformatics analysis suggested that ATF3, ID1, FOXM1, EZH2 and MITF may be crucial to parathyroid carcinogenesis. Series test of cluster analysis segregated differentially expressed lncRNAs and mRNAs into several expression profile models, among which the ‘plateau’ profile representing components specific to parathyroid carcinogenesis was selected to build a co-expression network. Seven lncRNAs and three mRNAs were selected for quantitative RT-PCR validation in 16 PCa, 41 PAd and 4 PaN samples. Receiver-operator characteristic curves analysis showed that lncRNA PVT1 and GLIS2-AS1 yielded the area under the curve values of 0.871 and 0.860, respectively. Higher hybridization signals were observed in PCa for PVT1 and PAd for GLIS2-AS1. In conclusion, the current evidence indicates that PAd and PCa partially share common signalling molecules and pathways, but have independent transcriptional events. Differentially expressed lncRNAs and mRNAs have intricate interactions and are involved in parathyroid tumourigenesis. The lncRNA PVT1 and GLIS2-AS1 may be new potential markers for the diagnosis of PCa.
Search for other papers by Xianhui Ruan in
Google Scholar
PubMed
Search for other papers by Xianle Shi in
Google Scholar
PubMed
Search for other papers by Qiman Dong in
Google Scholar
PubMed
Search for other papers by Yang Yu in
Google Scholar
PubMed
Search for other papers by Xiukun Hou in
Google Scholar
PubMed
Search for other papers by Xinhao Song in
Google Scholar
PubMed
Search for other papers by Xi Wei in
Google Scholar
PubMed
Search for other papers by Lingyi Chen in
Google Scholar
PubMed
Search for other papers by Ming Gao in
Google Scholar
PubMed
There is no effective treatment for patients with poorly differentiated papillary thyroid cancer or anaplastic thyroid cancer (ATC). Anlotinib, a multi-kinase inhibitor, has already shown antitumor effects in various types of carcinoma in a phase I clinical trial. In this study, we aimed to better understand the effect and efficacy of anlotinib against thyroid carcinoma cells in vitro and in vivo. We found that anlotinib inhibits the cell viability of papillary thyroid cancer and ATC cell lines, likely due to abnormal spindle assembly, G2/M arrest, and activation of TP53 upon anlotinib treatment. Moreover, anlotinib suppresses the migration of thyroid cancer cells in vitro and the growth of xenograft thyroid tumors in mice. Our data demonstrate that anlotinib has significant anticancer activity in thyroid cancer, and potentially offers an effective therapeutic strategy for patients of advanced thyroid cancer type.
Search for other papers by Xi Wei in
Google Scholar
PubMed
Department of Radiotherapy and Oncology, the Second Affiliated Hospital of Soochow University, Suzhou, China
Search for other papers by Shang Cai in
Google Scholar
PubMed
Search for other papers by Rebecca J Boohaker in
Google Scholar
PubMed
Search for other papers by Joshua Fried in
Google Scholar
PubMed
Search for other papers by Ying Li in
Google Scholar
PubMed
Search for other papers by Linfei Hu in
Google Scholar
PubMed
Search for other papers by Yi Pan in
Google Scholar
PubMed
Search for other papers by Ruifen Cheng in
Google Scholar
PubMed
Search for other papers by Sheng Zhang in
Google Scholar
PubMed
Search for other papers by Ye Tian in
Google Scholar
PubMed
Search for other papers by Ming Gao in
Google Scholar
PubMed
Department of Molecular Radiation Oncology, Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Search for other papers by Bo Xu in
Google Scholar
PubMed
Anaplastic thyroid cancer (ATC) is an aggressive cancer with poor clinical prognosis. However, mechanisms driving ATC aggressiveness is not well known. Components of the DNA damage response (DDR) are frequently found mutated or aberrantly expressed in ATC. The goal of this study is to establish the functional link between histone acetyltransferase lysine (K) acetyltransferase 5 (KAT5, a critical DDR protein) and ATC invasiveness using clinical, in vitro and in vivo models. We analyzed the expression of KAT5 by immunohistochemistry and assessed its relationship with metastasis and overall survival in 82 ATC patients. Using cellular models, we established functional connection of KAT5 expression and C-MYC stabilization. We then studied the impact of genetically modified KAT5 expression on ATC metastasis in nude mice. In clinical samples, there is a strong correlation of KAT5 expression with ATC metastasis (P = 0.0009) and overall survival (P = 0.0017). At the cellular level, upregulation of KAT5 significantly promotes thyroid cancer cell proliferation and invasion. We also find that KAT5 enhances the C-MYC protein level by inhibiting ubiquitin-mediated degradation. Further evidence reveals that KAT5 acetylates and stabilizes C-MYC. Finally, we prove that altered KAT5 expression influences ATC lung metastases in vivo. KAT5 promotes ATC invasion and metastases through stabilization of C-MYC, demonstrating it as a new biomarker and therapeutic target for ATC.
Search for other papers by Pei-Pei Xu in
Google Scholar
PubMed
Search for other papers by Su Zeng in
Google Scholar
PubMed
Search for other papers by Xiao-Tian Xia in
Google Scholar
PubMed
Search for other papers by Zi-Heng Ye in
Google Scholar
PubMed
Search for other papers by Mei-Fang Li in
Google Scholar
PubMed
Search for other papers by Ming-Yun Chen in
Google Scholar
PubMed
Search for other papers by Tian Xia in
Google Scholar
PubMed
Search for other papers by Jing-Jing Xu in
Google Scholar
PubMed
Search for other papers by Qiong Jiao in
Google Scholar
PubMed
Search for other papers by Liang Liu in
Google Scholar
PubMed
Search for other papers by Lian-Xi Li in
Google Scholar
PubMed
Search for other papers by Ming-Gao Guo in
Google Scholar
PubMed
Our aims were to uncover the role of FAM172A (Family with sequence similarity 172 member A) in the pathogenesis of follicular thyroid carcinoma (FTC) and to evaluate its value in the differential diagnosis between malignant and benign thyroid follicular lesions. FAM172A expression was evaluated by q-PCR, immunoblotting and immunohistochemistry (IHC). The ability of proliferation, migration and invasion of cells were assessed by Cell Counting Kit-8 assay (CCK8), clone-formation and Transwell assays. Nude mouse tumorigenicity assays were used to investigate the role of FAM172A in the pathogenesis of FTC in vivo. The value of FAM172A in the differential diagnosis for FTC was assessed using 120 formalin-fixed paraffin-embedded (FFPE) tissues after the operation and 81 fine-needle aspiration biopsy (FNAB) samples before the operation. FAM172A was highly expressed in FTC tissues and FTC cell lines. Downregulation of FAM172A inhibited the proliferation, invasion and migration of FTC cells through Erk1/2 and JNK pathways. Subcutaneous tumorigenesis in nude mice showed that knockdown of FAM172A inhibited tumor growth and progression in vivo. The FAM172A IHC scores of 3.5 had 92% sensitivity and 63% specificity to separate FTC from benign/borderline thyroid follicular lesions, and 92% sensitivity and 80% specificity to discriminate FTC from benign thyroid follicular lesions in postoperative FFPE samples. The corresponding values were 75 and 78%, and 75 and 89% in preoperative FNA samples, respectively. FAM172A plays an important role in the pathogenesis of FTC through Erk1/2 and JNK pathways. FAM172A may be a potential marker for the preoperative diagnosis of FTC based on the IHC results of thyroid FNAB samples.
Search for other papers by Francis Worden in
Google Scholar
PubMed
Division of Hematology/Oncology, Endocrine Unit, Comprehensive Cancer Center Mainfranken, Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Radiotherapy Department, Institut Bergonie, Tianjin Medical University Cancer Hospital, Fondazione IRCCS Ca' Granda, Department of Pathophysiology and Transplantation, Nagoya University Hospital, Aichi Cancer Center Hospital, Seoul National University College of Medicine, Asan Medicine Center, Department of Internal Medicine, Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Institut Gustave Roussy, Department of Otorhinolaryngology: Head and Neck Surgery, University of Michigan Comprehensive Cancer Center, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA
Search for other papers by Martin Fassnacht in
Google Scholar
PubMed
Division of Hematology/Oncology, Endocrine Unit, Comprehensive Cancer Center Mainfranken, Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Radiotherapy Department, Institut Bergonie, Tianjin Medical University Cancer Hospital, Fondazione IRCCS Ca' Granda, Department of Pathophysiology and Transplantation, Nagoya University Hospital, Aichi Cancer Center Hospital, Seoul National University College of Medicine, Asan Medicine Center, Department of Internal Medicine, Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Institut Gustave Roussy, Department of Otorhinolaryngology: Head and Neck Surgery, University of Michigan Comprehensive Cancer Center, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA
Search for other papers by Yuankai Shi in
Google Scholar
PubMed
Search for other papers by Tatiana Hadjieva in
Google Scholar
PubMed
Search for other papers by Françoise Bonichon in
Google Scholar
PubMed
Search for other papers by Ming Gao in
Google Scholar
PubMed
Division of Hematology/Oncology, Endocrine Unit, Comprehensive Cancer Center Mainfranken, Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Radiotherapy Department, Institut Bergonie, Tianjin Medical University Cancer Hospital, Fondazione IRCCS Ca' Granda, Department of Pathophysiology and Transplantation, Nagoya University Hospital, Aichi Cancer Center Hospital, Seoul National University College of Medicine, Asan Medicine Center, Department of Internal Medicine, Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Institut Gustave Roussy, Department of Otorhinolaryngology: Head and Neck Surgery, University of Michigan Comprehensive Cancer Center, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Search for other papers by Yuichi Ando in
Google Scholar
PubMed
Search for other papers by Yasuhisa Hasegawa in
Google Scholar
PubMed
Search for other papers by Do Joon Park in
Google Scholar
PubMed
Search for other papers by Young Kee Shong in
Google Scholar
PubMed
Search for other papers by Johannes W A Smit in
Google Scholar
PubMed
Search for other papers by John Chung in
Google Scholar
PubMed
Search for other papers by Christian Kappeler in
Google Scholar
PubMed
Search for other papers by Gerold Meinhardt in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Search for other papers by Marcia S Brose in
Google Scholar
PubMed
Effective adverse event (AE) management is critical to maintaining patients on anticancer therapies. The DECISION trial was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 trial which investigated sorafenib for treatment of progressive, advanced, or metastatic radioactive iodine-refractory, differentiated thyroid carcinoma. Four hundred and seventeen adult patients were randomized (1:1) to receive oral sorafenib (400 mg, twice daily) or placebo, until progression, unacceptable toxicity, noncompliance, or withdrawal. Progression-free survival, the primary endpoint of DECISION, was reported previously. To elucidate the patterns and management of AEs in sorafenib-treated patients in the DECISION trial, this report describes detailed, by-treatment-cycle analyses of the incidence, prevalence, and severity of hand–foot skin reaction (HFSR), rash/desquamation, hypertension, diarrhea, fatigue, weight loss, increased serum thyroid stimulating hormone, and hypocalcemia, as well as the interventions used to manage these AEs. By-cycle incidence of the above-selected AEs with sorafenib was generally highest in cycle 1 or 2 then decreased. AE prevalence generally increased over cycles 2–6 then stabilized or declined. Among these AEs, only weight loss tended to increase in severity (from grade 1 to 2) over time; severity of HFSR and rash/desquamation declined over time. AEs were mostly grade 1 or 2, and were generally managed with dose interruptions/reductions, and concomitant medications (e.g. antidiarrheals, antihypertensives, dermatologic preparations). Most dose interruptions/reductions occurred in early cycles. In conclusion, AEs with sorafenib in DECISION were typically grade 1 or 2, occurred early during the treatment course, and were manageable over time.